VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
RGEN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
RGENRepligen Corporation
$139.83$7.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksRGENFinancials

Repligen Corporation (RGEN) Financials

30Y historyFree accessUpdated daily

Revenue growth has rebounded to 14.8% in 2026Q1, though operating margins remain constrained at 8.9% due to persistent overhead and acquisition-related costs.

RGEN Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01Mar'00Mar'99Mar'98Mar'97Mar'96
Sales/Revenue763.34M738.26M634.44M632.36M801.54M670.53M366.26M270.25M194.03M141.24M104.54M83.54M63.55M68.17M62.27M27.29M20.97M29.36M19.3M14.07M12.91M9.36M6.91M7.77M4.3M2.35M3.45M2.6M2.4M3.8M10.9M
Revenue Growth %17.36%16.36%0.33%-21.11%19.54%83.08%35.53%39.28%37.38%35.1%25.14%31.45%-6.78%9.48%128.16%30.14%-28.58%52.16%37.1%9.01%37.94%35.38%-11.03%80.67%83.3%-31.99%32.72%8.33%-36.84%-65.14%-35.5%
Cost of Goods Sold283.98M390.63M359.79M353.92M345.83M279.28M171.91M132.02M85.95M67.05M47.12M35.25M28.02M25.16M27.17M7.12M5.51M6.78M6.16M3.61M3.55M3.89M3.25M3.48M1.99M1.12M782.23K400K300K300K100K
COGS % of Revenue-52.91%56.71%55.97%43.15%41.65%46.94%48.85%44.3%47.47%45.07%42.2%44.1%36.91%43.64%26.08%26.26%23.08%31.92%25.68%27.5%41.53%46.98%44.78%46.33%47.85%22.67%15.38%12.5%7.89%0.92%
Gross Profit393.38M347.62M274.64M278.44M455.71M391.25M194.35M138.22M108.08M74.19M57.42M48.29M35.53M43.01M35.1M20.17M15.46M22.58M13.14M10.46M9.36M5.47M3.67M4.29M2.31M1.22M2.67M2.2M2.1M3.5M10.8M
Gross Margin %51.53%47.09%43.29%44.03%56.85%58.35%53.06%51.15%55.7%52.53%54.93%57.8%55.9%63.09%56.36%73.92%73.74%76.92%68.08%74.32%72.5%58.47%53.02%55.22%53.67%52.15%77.33%84.62%87.5%92.11%99.08%
Gross Profit Growth %-26.57%-1.36%-38.9%16.47%101.31%40.61%27.89%45.69%29.19%18.92%35.92%-17.39%22.54%73.97%30.45%-31.52%71.93%25.59%11.74%71.05%49.28%-14.57%85.87%88.68%-54.14%21.29%4.76%-40%-67.59%-40%
Operating Expenses326.82M288.05M309.76M230.74M231.04M224M113.07M98.14M82.09M60.18M38.21M30.44M22.76M20.04M23.72M20.55M21.23M18.7M-22.76M12.28M10.58M9.63M13.61M9.39M7.89M8.56M6.56M3.7M2.9M4M18.6M
OpEx % of Revenue-39.02%48.82%36.49%28.82%33.41%30.87%36.32%42.31%42.61%36.55%36.44%35.82%29.4%38.09%75.29%101.24%63.7%-117.93%87.29%81.95%102.92%196.79%120.77%183.34%364.61%190.07%142.31%120.83%105.26%170.64%
Selling, General & Admin284.13M290.51M263.37M218.58M215.83M183.87M93.41M78.69M66.32M51.51M30.85M24.7M17.15M12.7M13.23M8.02M7.07M5.93M10.17M6.36M5.42M4.6M4.71M4.16M2.53M2.49M2.48M1.6M1.3M2.4M4.9M
SG&A % of Revenue-39.35%41.51%34.57%26.93%27.42%25.5%29.12%34.18%36.47%29.51%29.57%26.99%18.63%21.24%29.38%33.72%20.21%52.72%45.19%41.96%49.11%68.12%53.52%58.72%106.23%71.88%61.54%54.17%63.16%44.95%
Research & Development54.77M54.18M43.2M42.72M43.94M34.27M19.66M19.45M15.77M8.67M7.36M5.74M5.61M7.34M10.49M12.53M14.16M12.77M7.24M5.92M5.16M5.04M6.48M5.23M5.36M5.79M3.75M1.8M1.4M1.4M12.3M
R&D % of Revenue-7.34%6.81%6.76%5.48%5.11%5.37%7.2%8.13%6.14%7.04%6.87%8.83%10.77%16.85%45.91%67.52%43.5%37.52%42.09%39.99%53.81%93.77%67.25%124.62%246.58%108.79%69.23%58.33%36.84%112.84%
Other Operating Expenses-2M-56.64M3.19M-30.57M-28.73M5.87M00262K000188K-110.65K26.4K000-40.17M0002.41M00276.85K324.41K300K200K200K1.4M
Operating Income66.57M59.58M-35.11M47.7M224.67M167.25M81.29M40.08M25.99M14.01M15.97M13.76M10.69M22.87M11.08M-374.07K-5.77M3.88M35.89M-1.83M-1.22M-4.16M-9.94M-5.09M-5.58M-7.33M-3.89M-1.5M-800K-500K-7.8M
Operating Margin %8.72%8.07%-5.53%7.54%28.03%24.94%22.19%14.83%13.39%9.92%15.28%16.48%16.82%33.55%17.8%-1.37%-27.5%13.21%186%-12.97%-9.45%-44.46%-143.77%-65.55%-129.67%-312.46%-112.74%-57.69%-33.33%-13.16%-71.56%
Operating Income Growth %-269.67%-173.61%-78.77%34.33%105.75%102.8%54.24%85.56%-12.33%16.06%28.74%-53.26%106.38%3062.84%93.51%-248.63%-89.19%2066.32%-49.63%70.69%58.14%-95.13%8.67%23.93%-88.48%-159.36%-87.5%-60%93.59%61.58%
EBITDA155.46M138.32M51.45M133.82M281.68M205.7M108.36M60.95M41.77M24.46M21.31M18.36M14.71M25.99M14.59M1.3M-4.39M4.96M36.72M-1.29M-821.46K-3.41M-9.05M-4.29M-5.32M-7.06M-3.57M-1.2M-600K-300K-6.4M
EBITDA Margin %20.37%18.74%8.11%21.16%35.14%30.68%29.58%22.55%21.53%17.32%20.38%21.98%23.15%38.12%23.43%4.77%-20.92%16.88%190.28%-9.14%-6.36%-36.38%-130.95%-55.23%-123.68%-300.67%-103.34%-46.15%-25%-7.89%-58.72%
EBITDA Growth %132.55%168.86%-61.55%-52.49%36.94%89.84%77.77%45.93%70.77%14.78%16.07%24.8%-43.39%78.1%1022.04%129.64%-188.51%-86.5%2954.43%-56.59%75.88%62.39%-110.95%19.32%24.6%-97.86%-197.16%-100%-100%95.31%63.84%
D&A (Non-Cash Add-back)88.89M78.75M86.56M86.11M57.01M38.45M27.07M20.87M15.78M10.45M5.33M4.59M4.02M3.11M3.51M1.67M1.38M1.08M824.63K539.03K398.43K756.26K886.71K802.23K257.54K276.85K324.41K300K200K200K1.4M
EBIT88.41M85.56M-6.3M59.21M220.3M164.82M71.35M35.44M25.99M13.69M19.22M13.46M11.14M23.01M11.33M-1.71M-17.34K-4.9M5.78M35.89M-1.83M-1.22M-4.16M-9.94M-5.09M-5.58M-7.33M-4.36M-2.76M-815.02K0
Net Interest Income-5.55M4.4M-22.57M-10.03M4M-12.54M-10.39M-9.29M-6.71M-6.44M-3.77M-32K-50K-50K-56.71K0-26.17K-1.97K-2.96K000000000000
Interest Income27.24M27.57M006.98M176K1.74M000000000000000000000000
Interest Expense33.55M23.17M22.57M10.03M2.98M12.71M12.13M9.29M6.71M6.44M3.77M32K49.96K49.85K56.71K26.17K1.97K2.96K2.96K0696.86K0000000000
Other Income/Expense-9.01M2.81M8.08M9M-5.53M-13.71M-22.07M-13.93M-4.55M-6.76M-4.28M-341K447.58K140.82K-108.34K-2.35M5.72M868.07K1.89M39.76M936.07K1.92M1.18B5.4M1.12M2.05M3.52M1.86M1.96M315.02K500K
Pretax Income56.21M62.38M-27.04M56.71M219.14M153.54M59.22M26.15M21.44M7.25M11.69M13.42M11.14M23.01M11.27M-43.51K-4.9M5.77M37.93M-889.26K696.86K-2.98M-9.55M-4.54M-4.46M-5.28M-3.82M-2.5M-800K-500K-11.5M
Pretax Margin %7.36%8.45%-4.26%8.97%27.34%22.9%16.17%9.68%11.05%5.13%11.18%16.07%17.53%33.76%18.1%-0.16%-23.36%19.66%196.59%-6.32%5.4%-31.87%-138.13%-58.38%-103.7%-224.95%-110.6%-96.15%-33.33%-13.16%-105.5%
Income Tax4.82M13.49M-1.52M21.11M33.18M25.25M-709K4.74M4.82M-21.11M11K4.08M2.97M6.92M-2.88M-330.56K-834.77K26.7K827.47K889.26K-696.86K2.98M9.55M4.54M4.46M5.28M3.82M2.5M800K500K11.5M
Effective Tax Rate %8.57%21.62%5.63%37.23%15.14%16.45%-1.2%18.13%22.48%-291.18%0.09%30.38%26.65%30.07%-25.59%759.76%17.04%0.46%2.18%-100%-100%-100%-100%-100%-100%-100%-100%-100%-100%-100%-100%
Net Income51.4M48.89M-25.51M35.6M185.96M128.29M59.93M21.41M16.62M28.35M11.68M9.35M8.17M16.09M14.16M-43.51K-4.06M5.75M37.11M-889.26K696.86K-2.98M-9.55M-4.54M-4.46M-5.28M-3.82M-2.5M-800K-500K-11.5M
Net Margin %6.73%6.62%-4.02%5.63%23.2%19.13%16.36%7.92%8.56%20.07%11.17%11.19%12.86%23.61%22.73%-0.16%-19.38%19.57%192.3%-6.32%5.4%-31.87%-138.13%-58.38%-103.7%-224.95%-110.6%-96.15%-33.33%-13.16%-105.5%
Net Income Growth %323.66%291.64%-171.68%-80.86%44.95%114.08%179.88%28.85%-41.39%142.73%25%14.38%-49.23%13.68%32635.88%98.93%-170.72%-84.51%4272.73%-227.61%123.36%68.76%-110.51%-1.71%15.5%-38.32%-52.66%-212.5%-60%95.65%64.06%
Net Income (Continuing)51.4M48.89M-25.51M35.6M185.96M128.29M59.93M21.41M16.62M28.35M11.68M9.35M8.17M16.09M14.16M-2.15M-43.51K-4.06M5.75M37.11M-889.26K696.86K-2.98M-9.55M-4.54M-4.46M-5.28M-3.82M-2.54M-800K-500K
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)0.910.86-0.460.633.242.241.110.440.370.720.340.280.250.500.45-0.00-0.130.181.18-0.030.02-0.10-0.32-0.17-0.17-0.20-0.18-0.14-0.05-0.03-0.74
EPS Growth %842.57%286.96%-173.02%-80.56%44.64%101.8%152.27%18.92%-48.61%111.76%21.43%12%-50%11.11%-98.92%-172.22%-84.75%4127.3%-229.07%122.88%69%-88.24%0%15%-11.11%-28.57%-188.66%-61.67%95.95%64.42%
EPS (Basic)-0.87-0.460.643.352.331.140.440.380.740.350.280.250.510.46-0.00-0.130.191.20-0.030.02-0.10-0.32-0.17-0.17-0.20-0.18-0.14-0.05-0.03-0.75
Diluted Shares Outstanding56.67M56.56M55.94M56.38M57.45M57.26M53.89M49.21M45.47M39.15M34.1M33.58M33.26M32.41M31.25M30.78M30.75M31.29M31.32M30.38M30.69M30.06M29.69M26.81M26.64M26.55M21.54M18.02M16.5M16.67M15.53M
Basic Shares Outstanding56.35M56.23M55.94M55.72M55.46M55.02M52.55M48.34M43.77M38.23M33.57M32.88M32.5M31.67M30.91M30.78M30.75M30.96M30.83M30.38M30.13M30.06M29.69M26.81M26.64M26.55M21.54M18.02M16.5M16.67M15.37M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowImproving
Top Statement Risk

Bioprocessing inventory destocking cycles

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Rebounds From Destocking

According to the most recent quarterly filings, Repligen has successfully navigated a period of inventory recalibration, with revenue growth accelerating to 14.8% in 2026Q1, marking a significant recovery from the negative growth rates observed in early 2024 as the company moved past pandemic-era demand distortions.

The recent acceleration suggests that the primary destocking headwinds impacting the bioprocessing sector are beginning to subside. Investors should monitor whether this growth trajectory is sustainable or if it reflects a temporary replenishment of depleted customer inventories rather than a fundamental increase in underlying biologic production volumes.

Gross Margin Volatility Remains Elevated

As reported in financial statements, Repligen's gross margin profile has exhibited significant instability, fluctuating from a low of 23.2% in 2024Q4 to 55.7% in 2026Q1, reflecting the ongoing challenges of managing product mix and capacity utilization in a post-pandemic environment that warrants further investigation.

The wide variance in gross margins suggests that the company's cost structure remains highly sensitive to production volume fluctuations and potential inventory write-downs. While the recent expansion to 55.7% is encouraging, it remains unclear if this level represents a new structural baseline or a transient benefit from favorable product mix shifts.

Operating Leverage Constrained By Overhead

Based on the company's reported figures, operating income has struggled to scale proportionally with revenue, with operating margins reaching only 8.9% in 2026Q1, indicating that the firm's fixed cost base and recent acquisition-related expenses continue to exert significant pressure on overall profitability metrics.

The inability to consistently expand operating margins despite double-digit revenue growth suggests that the company's current SG&A and R&D spending levels may be misaligned with its current revenue scale. This warrants close scrutiny of management's ability to drive operational efficiencies as the business moves beyond the integration phase of its recent acquisitions.

Earnings Quality Obscured By Volatility

Analysis of the income statement reveals that net income remains highly inconsistent, with quarterly figures swinging from a $33.9 million loss in 2024Q4 to an $8.3 million profit in 2026Q1, largely driven by non-operating items and the impact of periodic stock-based compensation charges.

The erratic nature of the bottom line suggests that GAAP earnings may not currently serve as a reliable indicator of the company's core operational health. Investors should focus on the underlying drivers of cash generation rather than reported net income, which appears heavily influenced by accounting adjustments and integration-related costs.

RGEN — Frequently Asked Questions

Quick answers to the most common questions about buying RGEN stock.

What was Repligen Corporation's (RGEN) revenue in 2025?

For fiscal year 2025, Repligen Corporation (RGEN) reported total revenue of $738.3M. This represents a 6673.0% increase compared to $10.9M in 1996.

Is Repligen Corporation (RGEN) profitable?

Repligen Corporation (RGEN) is profitable, generating $48.9M in net income for the fiscal year ending 2025 with a net profit margin of 6.6%.

What is Repligen Corporation's operating profit margin?

Repligen Corporation (RGEN) reported an operating income of $59.6M, resulting in an operating profit margin of 8.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Repligen Corporation's gross profit and gross margin?

Repligen Corporation (RGEN) generated $347.6M in gross profit for the year, representing a gross profit margin of 47.1%. This demonstrates the company's core pricing power and production efficiency.